Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cerecin
The primary objective is to assess the efficacy of AXONA (medium chain triglycerides \[MCTs\]) when used alone or in combination with other agents in patients with mild-to-moderate Alzheimer's disease (AD) in routine clinical practice.
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female outpatients aged ≥ 50 years with a diagnosis of probable AD of mild-to-moderate severity
MMSE score between 14 and 24 inclusive at the initiation of AXONA treatment (if available)
Has received Axona for a duration of ≥ 6 months
Must be at least 21 years of age, has been the primary caregiver since prior to the initiation of Axona, provides at least 4 hours of supervision or direct assistance per day for the patient and is able to perform assessments.
You may not be if
MMSE score \< 14 at the time when AXONA treatment was initiated
Presence of co-morbid disease known to adversely impact cognitive function (e.g., Parkinson's disease, history of cerebral infarcts, dementia with Lewy bodies)
